NCT00697749View on ClinicalTrials.gov

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype

PHASE3CompletedINTERVENTIONAL

Enrollment

230

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

January 31, 2000

Study Completion Date

January 31, 2000

Conditions

Hepatitis B

Interventions

BIOLOGICAL

HBV-MPL vaccine 208129

2-dose intramuscular injection

BIOLOGICAL

Engerix™-B

3-dose intramuscular injection

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY